INM — InMed Pharmaceuticals Inc
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic
$1.35
+$0.03 (+2.27%)
InMed Pharmaceuticals Inc (INM) is a drug manufacturers - specialty & generic company listed on NASDAQ. It is led by Eric A. Adams B.S. Chem., M.I.B., based in 885 West Georgia Street, Vancouver, BC, Canada, V6C 3E8, with about 13 employees. InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with unmet medical needs. The company's lead product consists of INM-755, a cannabinol topical skin cream that has completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, a small molecule compound that acts as a selective dual CB1/CB2 agonist; and INM-900 for neurodegenerative diseases, as well as INM-901, a small molecule for treatment of Alzheimer's disease. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
Latest reported INM revenue for 2025-09-30 was $1.1M. Net income was -$1.7M. Revenue was down 77.3% from 2025-06-30 to 2025-09-30. INM currently screens at market cap $5.2M.
Use this INM page for company research — sector, financials, and the latest filing takeaway — not a live tape. The session quote (last, range, volume) lives on the INM quote page. Cached 10-K, 10-Q, 8-K, and Form 4 exhibits are on the INM SEC filings page. Lician reads the product cache first so this HTML stays unique to InMed Pharmaceuticals Inc even when a live quote feed is slow.
About InMed Pharmaceuticals Inc
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, develops a pipeline of prescription-based products in the United States. The company operates through two segments, InMed Pharmaceuticals and BayMedica Commercial. The InMed Pharmaceuticals segment researches and develops cannabinoid-based pharmaceuticals products. The BayMedica Commercial segment develops proprietary manufacturing technologies to produce and sell rare cannabinoids for the health and wellness industry. Its prescription-based products include rare cannabinoids and novel cannabinoid analogs for the treatment of diseases with unmet medical needs. The company's lead product consists of INM-755, a cannabinol topical skin cream that has completed Phase 2 clinical trial for the treatment of epidermolysis bullosa. It also develops INM-089, a small molecule compound that acts as a selective dual CB1/CB2 agonist; and INM-900 for neurodegenerative diseases, as well as INM-901, a small molecule for treatment of Alzheimer's disease. In addition, the company offers IntegraSyn, an integrated biosynthesis-based manufacturing approach for pharmaceutical-grade cannabinoids; and cannabichromene, cannabicitran, cannabidivarin, and tetrahydrocannabivarin. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
INM Key Statistics
Market Cap
$5.24M
Volume
48,518
Previous Close
$1.44
Day Range
$1.36 – $1.48
EPS
-$8.36
Revenue
$4.94M
Net Income
-$8.16M
Gross Profit
$0.00
Free Cash Flow
$0.00
Revenue Growth
+7.5%
Profit Margin
-165.1%
Employees
13
INM Financials
Annual income statement in USD. Latest reported periods first.
| Line | FY2025 | FY2024 | FY2023 | FY2022 |
|---|---|---|---|---|
| Revenue | $4.94M | $4.60M | $4.14M | $1.09M |
| Cost of Revenue | $0.00 | $0.00 | $0.00 | $0.00 |
| Gross Profit | $0.00 | $0.00 | $0.00 | $0.00 |
| Operating Income | $0.00 | $0.00 | $0.00 | $0.00 |
| Net Income | -$8.16M | -$7.68M | $7.90M | $18.60M |
| EPS (Diluted) | -$8.36 | -$20.14 | -$3.25 | -$33.17 |
Total Assets
$15.58M
Total Debt
$0.00
Shareholders' Equity
$0.00
Cash & Equivalents
$11.08M
Operating Cash Flow
-$7.77M
Free Cash Flow
$0.00
InMed Pharmaceuticals Inc Company Information
- President, CEO & Director
- Eric A. Adams B.S. Chem., M.I.B.
- Headquarters
- 885 West Georgia Street, Vancouver, BC, Canada, V6C 3E8
- Website
- www.inmedpharma.com
- Phone
- 604 669 7207
- IPO / Founded
- 2020-11-12
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic